肌萎缩侧索硬化（amyotrophic lateral ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

为探究循环激素和蛋白质组与肌萎缩侧索硬化症（ALS）的因果关系，明确潜在治疗靶点，研究人员开展孟德尔随机化（MR）研究。结果发现，遗传预测的较高游离睾酮（FT）水平与 ALS 风险降低 23% 相关，12 种血浆蛋白与 ALS 存在因果关联。这为 ALS 防治提供了新方向。

The use of oral edaravone for a total of 144 weeks is safe and well-tolerated among patients with amyotrophic lateral ...

Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...

MediciNova (MNOV) announced enrollment of the first patient in the NIH-funded Expanded Access Program trial to evaluate MN-166 in patients with ...

Scientists at Johns Hopkins Medicine say they have discovered how a group of proteins linked to Parkinson's disease and ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

At one point during her health journey, Chandler resident Erin Kienlen thought she had amyotrophic lateral sclerosis, or ALS.